These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32961526)

  • 1. Treatment With Liposomal Amphotericin B for All Confirmed Cases of Human Visceral Leishmaniasis in Brazil: A Budget Impact Analysis.
    Silva Ferreira de Carvalho IP; Peixoto HM; Sierra Romero GA; Fernandes de Oliveira MR
    Value Health Reg Issues; 2020 Dec; 23():77-84. PubMed ID: 32961526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
    Assis TSM; Rabello A; Cota G; Werneck GL; Azeredo-da-Silva ALF
    Rev Soc Bras Med Trop; 2019 Apr; 52():e20180272. PubMed ID: 30994802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The direct costs of treating human visceral leishmaniasis in Brazil.
    Assis TSM; Rosa DCP; Teixeira EM; Cota G; Azeredo-da-Silva ALF; Werneck G; Rabello A
    Rev Soc Bras Med Trop; 2017; 50(4):478-482. PubMed ID: 28954068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
    de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
    Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil.
    Dias Tourinho B; Figueiredo Amâncio F; Lencine Ferraz M; Carneiro M
    Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):163-171. PubMed ID: 28673017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
    Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C
    BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
    Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
    Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
    Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
    Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
    Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
    Coukell AJ; Brogden RN
    Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
    Gradoni L; Gramiccia M; Scalone A
    Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.
    Pandey K; Pal B; Siddiqui NA; Rabi Das VN; Murti K; Lal CS; Verma N; Babu R; Ali V; Kumar R; Das P
    Am J Trop Med Hyg; 2017 Nov; 97(5):1498-1502. PubMed ID: 29016288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.